APA (7th ed.) Citation

Olson, R., Liu, M., Bergman, A., Lam, S., Hsu, F., Mou, B., . . . Schellenberg, D. (2018). Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5. BMC Cancer, 18(1), 1. https://doi.org/10.1186/s12885-018-4859-7

Chicago Style (17th ed.) Citation

Olson, Robert, et al. "Population-based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to 5 Oligometastases: SABR-5." BMC Cancer 18, no. 1 (2018): 1. https://doi.org/10.1186/s12885-018-4859-7.

MLA (9th ed.) Citation

Olson, Robert, et al. "Population-based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to 5 Oligometastases: SABR-5." BMC Cancer, vol. 18, no. 1, 2018, p. 1, https://doi.org/10.1186/s12885-018-4859-7.